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CLCF-1 is a cytokine known for B-cell stimulation and for neurotrophic properties. We have identified CLCF-1 as a potential
injurious factor in the human renal disease focal segmental glomerulosclerosis (FSGS). We investigated its effects on renal cells
and renal function in in vitro and in vivo studies. Methods include measurement of the effect of CLCF-1 on phosphorylation of
target molecules of the JAK/STAT pathway, on cytoskeleton and cell morphology in cultured podocytes, on albumin permeability
of isolated rat glomeruli, and on tissue phosphorylation and urine albumin after acute or chronic CLCF-1 injection. In addition, cell
sorting was performed to determine the presence of cells expressing CLCF-1 in spleen and bone marrow of normal mice and the
effect of CLCF-1 infusion on splenic B-cell populations. CLCF-1 increased phosphorylation of STAT3 in multiple cell types, activated
podocytes leading to formation of lamellipodia and decrease in basal stress fibers, increased glomerular albumin permeability, and
increased STAT3 phosphorylation of peripheral blood cells and renal cortex. CLCF-1 increased urine albumin/creatinine ratio in
mice and increased B-cell expression of IgG in mouse spleen. We conclude that CLCF-1 has potentially important systemic effects,
alters podocyte function, and may contribute to renal dysfunction and albuminuria.

1. Introduction
CLCF-1 was originally described in 1999 by subtractive
hybridization using a cDNA library constructed from activated Jurkat lymphoma cells [1, 2]. It was found to have
neurotrophic activity and was termed neurotropin-1/B-cellstimulating factor-3 (NNT-1/BSF-3) [2]. It is expressed in
lymph nodes and spleen, bone marrow, peripheral blood
lymphocytes, ovary, placenta, kidney, pituitary, fetal liver,
and other tissues [3]. It can be actively secreted from cells
with heteromeric partners including cytokine receptor-like
factor-1 (CRLF-1) and soluble ciliary neurotrophic factor
receptor 𝛼 (sCNTFR𝛼) [4, 5]. CLCF-1 is important in neural
differentiation and survival and may serve as a ligand for

CNTFR𝛼 in supporting neural growth [6]. Its partner CRLF1 may play a role in response to injury [7]. There have been no
reports that implicate either of CLCF-1 or CRLF-1 in initiating
injury or causing disease.
We have been studying human focal segmental glomerulosclerosis (FSGS) for more than 20 years [8–15]. FSGS
describes a histopathological lesion characterized by loss
of podocyte foot process and segmental glomerular scarring. Clinical manifestations of FSGS include both steroidsensitive and steroid resistant nephrotic syndrome. Many
patients progress to renal failure. Genetic FSGS involves
mutations in proteins expressed by podocytes. The slit
diaphragms are highly specialized intercellular junctions
between podocytes that provide the final barrier to protein
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filtration [16–21]. In the majority of patients with FSGS,
no genetic abnormalities have been identified. After renal
transplantation, FSGS recurs in 30 to 50% of patients [11, 21–
23]. We and others have shown that plasma or serum of
such patients impairs glomerular barrier function and affects
the morphology of cultured immortalized podocytes and
have employed in vitro assays to direct efforts to identify
molecules that may lead to FSGS and its posttransplant
recurrence [8, 24–26]. We have used affinity chromatography
and mass spectrometry to identify CLCF-1 as a potential
plasma permeability factor in FSGS [15].
The role of CLCF-1 and related cytokines in control of the
function of mature cells has not been studied exhaustively.
The series of studies described here document the presence of
cells that express CLCF-1 in mouse bone marrow as well as the
effect of CLCF-1 on differentiation of B cells recovered from
the spleen after CLCF-1 infusion and on relevant signal pathways in circulating blood cells, renal cortex, glomeruli, and
tubules, and on cultured podocytes. Studies of the glomerular
barrier in vitro and of albuminuria in mice confirm the
relevance of these effects to renal function. The results are
consistent with our postulate that CLCF-1 may contribute
to human renal disease, specifically FSGS in patients with
recurrence after renal transplant.

2. Methods and Materials
2.1. Reagents and Solutions. Recombinant human CLCF1 (rhCLCF-1) and monoclonal anti-CLCF-1 antibody were
obtained from R&D Systems, Minneapolis, MN. Buffers
and media were prepared using chemicals obtained from
Sigma-Aldrich (St. Louis, MO). These reagents were stored
following the vendors’ guidelines. Working solutions were
prepared in medium containing 5% BSA. The JAK2 inhibitor
BMS-911543 was obtained from ChemieTek, Indianapolis,
IN. Stock solutions were prepared and stored following
instructions of suppliers/manufacturers.
2.2. Animals. Studies were carried out using protocols approved by the Institutional Animal Care and Use Committee
(IACUC), Safety Subcommittee, and the R&D Committee at
the Medical College of Wisconsin or the VA Medical Center,
Kansas City, MO. All animals were maintained at AAALACapproved facilities at 68–78∘ F ambient temperature and 30–
70% humidity under 12/12-hour light and dark cycles with
unrestricted access to food and water.
2.2.1. Mice for Studies of JAK and STAT Phosphorylation
and Albuminuria. The 1–12-week-old male C57B6 mice 1
(Charles River Laboratories, Indianapolis, IN) were used to
study effects of intraperitoneal (IP) injection of CLCF-1, 1–
10 𝜇g/kg/day for up to 3 days, or infusion of CLCF-1 by
osmotic minipump at a dose of 10 𝜇g/kg/day for up to 28
days. Blood samples were drawn by venipuncture at intervals
after injection and kidneys were obtained at sacrifice under
anesthesia. Urine was collected by spontaneous voiding.
2.2.2. Mouse Bone Marrow and Spleen Cells Analyzed for
CLCF-1 Expression. Cells were obtained from bone marrow

Journal of Immunology Research
and spleen of FVB mice (Charles River Laboratories) after
euthanasia under anesthesia. Cells were stained with rabbit
anti-CLCF-1 polyclonal serum (Santa Cruz Biotechnology
NNT-1/BSF-3 (FL-225)) which was raised against a human
CLCF-1 peptide and cross-reacts with mouse and rat protein.
Normal rabbit IgG (catalog #: sc2027) was used as an isotype
control. Detection was performed with goat-anti-rabbitFITC (Pharmingen 554020). Fixation and permeabilization
solution from eBioscience was used as recommended. The
data were analyzed using Becton-Dickenson FACSCalibur
and FlowJo single cell analysis software.
2.2.3. Rats for Isolation of Glomeruli for Permeability Studies. Adult male Sprague-Dawley rats (7-8 weeks old, 200–
250 g body weight) were obtained from Harlan, Madison,
WI. Glomeruli were isolated from renal cortex of kidneys
removed immediately after euthanasia under anesthesia.
Details of glomerular isolation are described below.
2.3. Isolation of Mouse Bone Marrow or Spleen Cells
for Expression of CLCF-1 or IgG1
2.3.1. Expression of CLCF-1 by Mouse BM Cells. Cells were
retrieved from bone marrow of normal mice using gradient
density centrifugation. They were stained with antibodies for
CD3, CD45R, TER119, Gr-1, and CD11b. They were analyzed
using 4-color FACSCalibur (BD Bioscience) flow cytometer.
2.3.2. Expression of IgG in Splenocytes after Infusion of CLCF1. Mouse spleen mononuclear cells were isolated by FicollHistopaque gradient density centrifugation and incubated
with Fc Block (BD Biosciences) in PBS 0.5% BSA. Cells
were washed and stained with a combination of APC-labeled
rat anti-CD19 mAb and Alexa 488-labelled rat anti-IgG1
(both from BD Bioscience) for 30 min on ice. Fluorescence
was analyzed using a FACSCalibur (BD Biosciences) flow
cytometer [27]. Results were expressed as percentage of B
cells expressing IgG1 (CD19+ IgG1 double positive cells) in
whole spleen.
2.4. Human Peripheral Blood Samples
2.4.1. Human Subjects. The Institutional Review Board of the
University of Kansas Medical Center and of Medical College
of Wisconsin or NIDDK, NIH (Kopp), approved all studies of
human specimens obtained during the tenure of the authors
at the respective institutions. Specimens collected specifically
for this study were obtained after written informed consent
from the donors. The diagnosis of FSGS was confirmed by
renal biopsy in the native kidney. Recurrent FSGS after renal
transplantation was defined by nephrotic range proteinuria in
the early posttransplant period and, in most cases, by biopsy
of the allograft showing podocyte foot process effacement.
2.4.2. Human Serum and Plasma Specimens for Measurement
of CLCF-1. Serum or plasma was obtained from samples
of peripheral blood obtained from normal volunteers and
FSGS patients with proteinuria recurrence following kidney
transplant. Plasma concentrations of CLC-1 were determined
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using immunocapillary electrophoresis. This technique is linear across concentrations from 200 to 10 pg/mL and permits
measurement of concentrations as low as 10 pg/mL.

CLCF-1 on STAT3 (Tyr 705) phosphorylation was measured.
Normalized intensity ratios were used to prepare bar graphs
shown.

2.5. Glomerular Albumin Permeability (𝑃alb ) Assay Using
Glomeruli Isolated from Normal Rats. Glomeruli from
Sprague-Dawley rats were used to study changes in
glomerular filtration barrier characteristics using an in
vitro assay established in our laboratory [28]. Briefly, rat
glomeruli were isolated and suspended in a physiological
solution (pH 7.4) containing bovine serum albumin (BSA)
5 gm/dL (isolation/incubation buffer). Isolated glomeruli
were treated with control or test agents for 15 minutes at 37∘ C.
A video-image was recorded and medium was changed to 1%
BSA while additional images were recorded. The change of
medium produced an oncotic gradient across the glomerular
capillary wall and caused fluid influx into the capillaries
and an increase in glomerular volume. Glomerular volume
was estimated from the geometric mean of 4 glomerular
diameters measured at 45∘ angles. The change in volume
(Δ𝑉) of each glomerulus in response to the oncotic gradient
was calculated as Δ𝑉 = (𝑉final − 𝑉initial )/𝑉initial × 100%. The
increase in glomerular volume (Δ𝑉) was used to calculate
convectional albumin permeability (𝑃alb ) which describes
the movement of albumin consequent to water flow. In
normal glomeruli, 𝑃alb is zero and the ratio of Δ𝑉 of control
and experimental glomeruli are equal. 𝑃alb increases with
loss of the permeability barrier and the ratio of Δ𝑉 of
experimental glomeruli to Δ𝑉 of experimental glomeruli
falls proportionately. In each experiment, 5 glomeruli from
each experimental condition for each rat were measured and
the average was used in further analyses. Experiments were
repeated in triplicate.

2.7. Cell Culture and Confocal Microscopy. Immortalized
murine podocytes [29] were grown on collagen coated glass
coverslips at 33∘ C to subconfluence and then transferred to
37∘ C to permit differentiation. They were treated with CLCF-1
or other reagents, fixed in 4% paraformaldehyde in phosphate
buffered saline (PBS) for 15 minutes at room temperature, and
then washed with PBS. After fixation, cell membranes were
permeabilized with 0.1% Triton-X100 in PBS (10 minutes)
and 0.05% Tween-20 (10–15 minutes). The actin cytoskeleton
was stained using Alexa Fluor 568 Phalloidin, Invitrogen,
A12380. Nuclei were stained with Hoechst 33342. Cover slips
were mounted in 5% 𝑛-propyl gallate in buffered glycerol
(glycerol : PBS, 9 : 1). Cells were viewed using a Leica DMI
4000 B confocal microscope. 𝑍-sections 0.25 𝜇m in thickness
were obtained for analysis. Images were taken using a 40x
objective lens and a 561 nm laser. Laser intensity, gain settings, scaling, individual section depth, and pinhole settings
were kept constant through the entire experiment so that
intensities can be compared directly. Images were analyzed
using Image J software. Parameters measured included cell
perimeter and area, total intensity of actin, and presence and
density of peripheral actin arcs as well as proportion of the
cell periphery that was made up of lamellipodia. The number,
thickness, and parallel configuration of basal actin fibers were
assessed semiquantitatively.

2.6. Western Blotting and Determination of STAT3 Phosphorylation. Tissue was homogenized in lysis buffer containing Sigma Fast Protease Inhibitor (S8820, 119K8203 SigmaAldrich, St. Louis, MO) and phosphatase inhibitors (P5726
and P0044, Sigma-Aldrich) using a sonicator and the lysate
was centrifuged at 12,000 g for 5 minutes. Total protein was
determined using a kit based on Lowry’s assay (Bio-Rad,
Hercules, CA). The supernatant was frozen at −70∘ C. Total
protein was electrophoresed by SDS-PAGE using TGX gels
(Bio-Rad) followed by electrotransfer to PVDF membrane
and detection using specific primary antibodies. Rabbit antipSTAT3 (Tyr705 D3A7, Cell Signaling catalog # 9131, 1 : 1000
dilution) was used in 5% BSA TBST. Mouse anti-𝛽-actin
(Sigma catalog # A5441, 1 : 10000) was used in 5% dry milk
in TBST. HRP-conjugated secondary antibodies for pSTAT3
(Tyr 705) and 𝛽-actin were goat anti-rabbit HRP conjugate
(Bio-Rad, catalog # 1705046, 1 : 10,000 dilution) and goat
anti-mouse HRP conjugate (Bio-Rad, catalog # 170-5047,
1 : 10,000), respectively. ECL Prime Western Blotting Detection reagent (GE Health Sciences, Piscataway, NJ) was used
for chemiluminescence reaction and images were obtained
using Kodak Gel Logic 2200 imaging system (Carestream
Health, New Haven, CT). Image intensity data were normalized by loading control 𝛽-actin. Normalized intensity
ratios were used to prepare bar graphs shown. The effect of

2.8. Renal Histology. Renal cortex was examined by light
microscopy after infusion of CLCF-1 for 28 days. Tissue was
fixed in formalin, embedded in paraffin, and stained with
Jones stain and counterstained with H and E. Additional
sections were stained for pSTAT Tyr705 using a phosphoTyr705-specific Stat3 antibody from Cell Signaling (# 9145).
2.9. Statistical Analyses. Values of studies with 2 groups were
compared using Student’s 𝑡-test. In studies in which more
than 2 groups were compared, ANOVA was used. 𝑃 < 0.05
was accepted as significant.

3. Results
3.1. Demonstration of CLCF-1 Producing Cells in Mouse
Bone Marrow by Flow Cytometric Analysis. Studies were
performed to demonstrate potential hematopoietic sources
of CLCF-1 in the mouse using intracellular staining and
flow cytometry. Ly-6G, formerly known as the myeloid
differentiation antigen Gr-1, is a GPI-anchored protein. In
the bone marrow, the level of antigen expression is directly
correlated with granulocyte differentiation and maturation.
It is also transiently expressed on monocytes in the bone
marrow. In the periphery, Ly-6G is expressed predominantly
on neutrophils. A set of representative plots are shown to
compare the normal rabbit IgG and immune serum. A
subset of hematopoietic cells showed specific staining with
the anti-CLCF-1 polyclonal serum. These cells were negative
for CD3, CD45R, and TER119 (not shown) but positive
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Figure 1: (a) Expression of CLCF-1 in bone marrow of FVB mouse. Cells were isolated from bone marrow (BM) and subjected to flow
cytometry. Approximately 11% of BM cells stained with anti-CLCF-1. These cells were also positive for the myeloid differentiation antigen
GR-1 but did not express markers for B or T lymphocytes (see text). A representative experiment is shown.

for Gr-1 (shown) and CD11b (not shown). Approximately
10% of bone marrow cells and 1-2% of splenocytes stained
with anti-CLCF-1. The CLCF-1 expressing cells appear to be
myeloid cells, most likely neutrophils, and do not include T
or B lymphocytes or erythroid cells. See Figure 1(a). LPS or
ConA stimulation of splenocytes did not result in increased
numbers of CLCF-1 positive cells (data not shown). These
findings suggest that hematopoietic cells producing CLCF-1
are present in the mouse in the basal state and that they are
not increased by immune stimulation.
3.2. Effect of Injection of CLCF-1 on B-Cell Expansion. The
percentage of splenic B cells that expressed IgG was increased
after CLCF-1 infusion by minipump for 28 days. The result of
duplicate studies is shown in Figure 2(a). No data for earlier
time points are available. This finding is expected from prior
understanding of CLCF-1 as a B-cell stimulating cytokine.
3.3. Phosphorylation of Peripheral Blood Cells and Renal
Cortex of Mice after Acute Injection or Chronic Injection of
CLCF-1. Acute intraperitoneal injection of CLCF-1 led to
phosphorylation of STAT3 in peripheral blood cells. pSTAT
was present within 15 minutes of injection and peaked within
1 hour. Increased pSTAT3 persisted for 72 hours after a single
injection but was decreasing toward baseline at the end of
this period, Figure 2(b). pSTAT3 was also increased in renal
cortex at the same time intervals after an injection of CLCF1. See Figure 2(c). Findings confirm that CLCF-1 affects cells
outside its traditionally recognized targets of immune cells.
Of note, the signaling effect of CLCF-1 is greater in magnitude
and persists longer in renal cortex than it does in peripheral
blood cells.

3.4. Effects of CLCF-1 on Glomerular 𝑃alb and Dependence on JAK2 Phosphorylation. Recombinant human CLCF1 (rhCLCF-1, CLCF-1) at subnanomolar concentrations
of 0.05–100 ng/mL increased glomerular 𝑃alb in a dosedependent manner. A significant increase in 𝑃alb was evident
at CLCF-1 concentrations as low as 0.05 ng/mL. A maximal
increase was observed at 5 ng/mL (𝑃 < 0.001). Responses to
concentrations of 0.5 and 5 ng/mL are shown in Figure 3(a).
Plasma from patients with recurrent FSGS typically increases
𝑃alb to between 0.7 and 0.8 [8, 10]. Anti-CLCF-1 monoclonal
antibody blocked the increase in 𝑃alb caused by CLCF-1
(Figure 3(a)). For the studies shown, 𝑃alb was measured after
glomerular incubation with CLCF-1 (5 ng/mL) or with CLCF1 and anti-CLCF-1 antibody (50 mg/mL) for 15 min. AntiCLCF-1 mAb also markedly diminished the 𝑃alb response to
plasma of patients with recurrent FSGS to as little as 5%
of uninhibited values (data not shown). Inhibition of 𝑃alb
activity of CLCF-1 by mAb was specific as evidenced by
the fact that neither preimmune rabbit IgG (control) nor
antibodies to TNF, TGF, or IL-6 protected glomeruli from
the effects of CLCF-1 (data not shown). These observations
document the capacity of CLCF-1 to impair the glomerular
barrier to albumin.
To test the hypothesis that the effect of CLCF-1 depends
on JAK2 activation we incubated glomeruli with the JAK2
inhibitor BMS911543 prior to addition of CLCF-1. This
inhibitor is specific for the JAK2 isoform. BMS911543
markedly decreased the effect of CLCF-1 on 𝑃alb ; see
Figure 3(b). The inhibition of CLCF-1 effect on 𝑃alb is consistent with the hypothesis that JAK2 phosphorylation is a
necessary initial step in control of glomerular permeability.
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Figure 2: Total pSTAT3 in (a) peripheral blood cells and (b) renal cortex was determined by Western blot analysis of lysates as described
in Methods and Materials. Values are expressed as the ratio of pSTAT to 𝛽-actin. Results of a single experiment are shown. Note that the
maximum increase in pSTAT3 is nearly 8-fold greater in kidney cortex compared to blood cells. (c) Mouse spleen mononuclear cells were
isolated and analyzed as described in Methods and Materials. Results are expressed as percentage of B cells expressing IgG1 (CD19+/IgG1+).
Mean of 3 determinations in each of the 2 mice was used to calculate values, expressed as mean ± standard deviation. CD19+/IgG1+ cells were
increased after infusion of CLCF-1. ∗ 𝑃 < 0.01.
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treated with BMS911543 alone. CLCF-1 increased 𝑃alb was blocked by pretreatment with BMS911543. ∗ 𝑃 < 0.001 versus BMS911543 alone or
CLCF-1 after BMS911543.
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(a)
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(c)

Figure 4: Immortalized podocytes were incubated with either (a) vehicle (b, c) 10 ng/mL CLCF-1 for (b) 15 minutes or (c) 30 minutes.
Subsequently, cellular actin was stained as described in Methods and Materials and 0.25 𝜇m sections were visualized by confocal microscopy.
Note parallel actin bundles in central portion of control cell (a), compared to the decrease in intensity of central actin bundles and loss of
parallel pattern in the cells treated with CLCF-1 (c). Lamellipodia are present in nearly the entire circumference after 30 minutes of incubation
(c).

3.5. Effects of CLCF-1 on Actin Cytoskeleton of Cultured
Podocytes. Incubation with CLCF-1 for up to 1 hour caused
marked changes in the configuration of the actin cytoskeleton
of cultured murine podocytes. Changes progressed with
duration of incubation and were concentration dependent.
Specifically, the intensity and ordered configuration of stress
fibers in the central part of the cells diminished. The number and extent of lamellipodia increased as did the extent
and intensity of actin arcs associated with lamellipodia.
Lamellipodia, measured as percent of the cell circumference
occupied, increased from 21 ± 7% to 82 ± 7% after 1 hour
of incubation. Cell area and total actin intensity did not
change. These changes are consistent with activation of the
cell toward a more motile phenotype that may be more
vulnerable to detachment under mechanical or metabolic
stress. Representative cell images of control podocyte and
of cells after incubation for 15 and 30 minutes are shown in
Figures 4(a), 4(b), and 4(c).
3.6. Effects of Infusion of CLCF-1 on Phosphorylation of
Cells of Mouse Renal Cortex and on Mouse Albuminuria.
A single injection of CLCF-1 significantly increased both
renal cortical pSTAT and urine albumin/creatinine ratio
(UACR). Results of a representative experiment are shown
in Figure 5(a). In this experiment, both pSTAT3 and UACR
increased significantly. Chronic infusion of CLCF-1 for 28
days increased the UACR values from control of 0.20 ± 0.05,
𝑁 = 10, to post-28-day infusion of 0.57 ± 0.46. 𝑁 = 4 (𝑃 <
0.02). Figure 5(b) shows results of Western blots for pSTAT3
in control and 3 individual mice after 28 days of SLSF-1
infusion. Immunohistochemistry showed increased pSTAT3
in cells of the glomerulus, renal tubules, and renal arterioles.
Segmental lobular solidification with mesangial expansion
and obliteration of capillaries was present in rare glomeruli
after infusion but not in control kidneys. pSTAT3 was present
in nuclei of glomerular cells after treatment with CLCF-1 but
not in those treated with vehicle. Results of histology and

immunohistochemistry are shown in Figures 5(c) and 5(d).
Taken together, these results confirm that CLCF-1 activates
pSTAT3 in glomerular and other renal cells and increases
albuminuria.

4. Discussion
4.1. CLCF-1, a Member of the IL-6 Family of Cytokines. CLCF1 has a predicted molecular weight that is 22 kDa. It shares
19–27% homology with other IL-6 family members. It is
predicted to contain 𝛼-helices and has 1 potential N-linked
glycosylation site. Alternative names include cardiotrophinlike cytokine 1 (CLC-1), B-cell stimulatory factor-3 (BSF3),
and novel neurotrophin-1 (NNT-1) [30]. CLCF-1 maps to
chromosome 11q13.3 [2, 3]. It appears to be secreted efficiently
only with a partner such as cytokine receptor-like factor-1
(CRLF-1) or soluble ciliary neurotrophic factor receptor 𝛼
(sCNTFR). It may associate with CRLF-1 in the circulation
and many commercially available preparations for recombinant CLCF-1 are supplied as the compound cytokine CLCF1/CRLF-1. CLCF-1, like other members of the interleukin-6
family, is involved in cell signaling through phosphorylation
of glycoprotein 130 (gp130) [5]. It activates a complex receptor
consisting of gp130, ciliary neurotrophic factor receptor
(CNTFR𝛼), and leukemia inhibitory factor receptor (LIFR𝛼)
[4]. An alternative receptor has been detected on B cells
by the use of labeled CLCF-1 but has not been completely
characterized [31]. The requirements for interactions between
CLCF-1 and related cytokines and specific receptors are under
active investigation. Binding partners of these cytokines and
interactions with receptor proteins may be cell-type specific.
For instance, IL-27-𝛼 deficient cells can be activated by a heterodimer composed of CRLF-1 and p28 (p28/CRLF-1); this
heterodimer activates and induces plasma cell differentiation
and IgM, IgG2c, and IgG1 production [27]. Additionally,
the compound cytokine CLCF-1/CRLF-1 acts only through
the canonical receptor for CLCF-1 (gp130-LIFR𝛽-CNTFR𝛼),

Fold increase after CLCF-1
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Figure 5: (a–d) Effect of acute injection or 28-day infusion of CLCF-1 on urinary albumin creatinine ratio (UACR) and renal histology and
pSTAT3 expression in mice. (a) Renal cortical pSTAT3 and urine albumin creatinine (UACR) ratio 24 hours after a single injection of CLCF-1.
Results for one experiment with 12 individual mice are shown as ratio of postinjection values to control values for pSTAT3 and postinjection
to preinjection values for individual mice for UACR. pSTAT3 increased to 3.0 ± 1.8 (95% confidence interval 2.8 to 5.1) and UACR increased by
1.62 ± 0.37-fold versus preinjection level (95% confidence interval 1.38 to 1.85). Values are mean ± SD, 𝑁 = 12. (b) CLCF-1 infusion increases
pSTAT3 expression in renal cortex. After 4 weeks of infusion of CLCF-1 or vehicle (control) by minipump, mouse renal cortex was harvested
and lysates were examined for pSTAT3 expression by Western blot. Results are shown for cortex of 3 individual mice that received CLCF-1
and one control mouse. (c) Histology of mouse renal cortex after 4 weeks of CLCF-1 or vehicle (control) infusion. Kidneys were harvested
from treated and control mice, and histologic sections were prepared and stained as described in Methods and Materials. (A) Control mouse
(Jones silver stain). Glomeruli showed normal cellularity and mesangial matrix without evidence of sclerosis (>150 glomeruli counted). Scale
bar = 25 𝜇m. (B) CLCF-1 infusion (28 days; Jones silver stain). Renal cortex after 28 days of CLCF-1 infusion. Rare glomeruli (2 in >150
glomeruli counted) showed segmental sclerosis, with collapse of capillaries and segmental increase in matrix (arrow). Scale bar = 25 𝜇m. (C)
Anti-pSTAT3 staining of renal cortex from control treated mouse. No staining was evident. Scale bar = 25 𝜇m. (D) Anti-pSTAT3 staining
of renal cortex from mouse treated for 28 days with infusion of CLCF-1. Occasional glomerular epithelial cells showed pSTAT3 staining
(arrowheads). Scale bar = 25 𝜇m. (d) Anti-pSTAT3 staining of renal cortex from mouse treated for 28 days with infusion of CLCF-1. Focal
staining of tubules (A), as well as smooth muscle and endothelial cells (B), is indicated by arrows. No staining was observed in sections of
control mouse kidneys. Scale bar = 50 𝜇m.
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while CNTF can activate cells through an alternate receptor
complex gp130- LIFR𝛽-IL6R when CNTFR𝛼 is absent and
IL6R is present [32].
CLCF-1 and related molecules are known for their trophic
effects on neurons and other cells during development.
CLCF-1 is required for motor neuron development and mice
lacking it die shortly after birth because they cannot suckle
[6, 33]. Additional targets of CLCF-1 action include increased
ACTH secretion by corticotroph AtT-20 cells and murine
pituitary tissue which is blocked by suppressor of cytokine
signaling (SOCS)-3 [34], a significant role in control of
branching during fetal lung development [35], and a role
in diminishing fibrosis in bleomycin induced lung injury
[7].
CRLF-1 has been found in the immature kidney and
appears to affect renal development [36]. A case of renal dysplasia associated with cold sweating syndrome and potential
deficiency of CLCF-1/CRLF-1 has been reported [37]. Human
disease related to inactivation of CLCF-1 leads to autonomic
dysfunction in the Crisponi syndrome, also termed cold
sweating syndrome [30]. Signaling mediated by CLCF-1
appears to depend primarily on activation of JAK/STAT
pathways. Modulation of these pathways includes negative
regulation via SOCS [1, 34] as well as activation by specific
receptors. Examples of studies of CLCF-1 receptor activation
and signaling include phosphorylation of gp130, LIFR-𝛽, and
STAT3 in human neuroblastoma cells and activation of NF𝜅B
and SRE reporter constructs [3]. In addition CLCF-1 may
form an active heterodimer with its secretory partner CRLF-1
[5]. This heterodimer activates B cells but, paradoxically, we
have found that it blocks the effect of CLCF-1 on glomeruli
or podocytes [38]. Overexpression of CLCF-1 in transgenic
mice, under control of the apolipoprotein E promoter, led to
B-cell hyperplasia with particular expansion of the mature
follicular B-cell subset in the spleen and the prominent
presence of plasma cells. Mice showed elevated serum levels
of IgM, IgE, IgG2b, IgG3, anti-dsDNA Abs, and amyloid A.
They produced high amounts of Ag-specific IgM, IgA, and
IgE and low amounts of IgG2a and IgG3 [39].
4.1.1. JAK/STAT Pathway and Transcription. CLCF-1 and
related cytokines affect cell function through phosphorylation of molecules of the JAK/STAT pathway. We have
found that JAK2 and STAT3 are the predominant isoforms in
glomeruli and podocytes of mice and rats (unpublished data).
STAT3 effects appear to be determined by posttranslational
modifications, dimerization, and nuclear translocation. Activation of STAT3 involves phosphorylation at tyrosine 705
(Y705), nuclear translocation, and binding to interferon-𝛾
activated sequences for transcription [40–42]. In addition,
phosphorylation of serine (S) residues in STATs (S727 in
STAT3) may affect STAT translocation in a variety of cell
specific ways [43]. STAT3 activation may also occur by
serine phosphorylation without tyrosine phosphorylation
[40]. Acetylation of STAT3 is responsible for its function as
a negative regulator of autophagy [44, 45] and it contributes
to oxidative changes in diabetic nephropathy [46]. The range
of STAT3 effects remains to be fully defined.
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4.1.2. CLCF-1 and the Kidney. CLCF-1 has been suggested as
a regulator of kidney development. CRLF-1 is enriched in the
ureteric bud and the CLCF-1/CRLF-1 complex caused phosphorylation of STAT3, a reaction typical of mesenchymalto-epithelial conversion. Incubation of rat metanephric mesenchyme with CLCF-1/CRLF-1 (3 nM) induced structures
expressing glomerular and tubular markers [36]. A transgenic
mouse with overexpression of CLCF-1 manifested increased
B-cell antibody production and increased level of serum
amyloid A, as cited above. In addition, these mice developed
nonamyloid mesangial deposits that contained IgM, IgG, and
C3 and showed a distinctive ultrastructure similar to that of
immunotactoid glomerulopathy. No mention of proteinuria
is made in the description of this phenotype [39]. We
identified activation of STAT3 in cells of glomeruli, renal
tubules, and blood vessels after infusion of CLCF-1 as shown
above.
4.2. CLCF-1 and FSGS. We have identified CLCF-1 in the
plasma of patients with FSGS who experience recurrence of
proteinuria and renal disease in the allograft after transplantation. Identification was based on the results of LC-MS/MS
of plasma after affinity purification using galactose coated
Sepharose beads [47]. A single peptide unique to CLCF1 was identified in the active plasma fraction of two FSGS
patients and was not identified in pooled plasma from normal
donors. No other cytokine was identified in plasma fractions
of patients or normal controls. These findings provided the
rationale for testing the activity of CLCF-1 as a regulator
of podocyte and glomerular function and as an inducer of
proteinuria. The current investigations verify that rCLCF-1
shows activity comparable to that of FSGS plasma in increasing glomerular 𝑃alb during in vitro testing. The permeability
activity was blocked by a monoclonal anti-CLCF-1 antibody
or by a specific JAK2 inhibitor. These findings are consistent
with the interpretation that JAK phosphorylation, such as
that caused by interaction of CLCF-1 with its receptor complex, is sufficient to alter glomerular function. In addition,
CLCF-1 activated cultured murine podocytes as evidenced by
altered cytoskeleton and increased pSTAT3. CLCF-1 also led
to an increase in albuminuria after it was injected into mice.
These are the first findings that suggest that CLCF-1 regulates
mature cells of nonhematological organs and that activation
of its receptors may contribute to disease.
4.3. Role of CLCF-1 in FSGS and Its Recurrence. The results
presented here implicate CLCF-1 as a potential “circulating factor” in recurrent FSGS. CLCF-1 is present in the
fraction of plasma of affected FSGS patients that carries
permeability activity. It acts promptly to initiate signaling
via the JAK/STAT pathway in glomerular podocytes as well
as in systemic cells. It alters the morphology of cultured
podocytes and the barrier function of glomerular capillaries.
Glomerular and podocyte responses are consistent with a
direct effect of CLCF-1 to alter function in a manner that
leads to proteinuria, the first sign of FSGS. The degree of
albuminuria/proteinuria in the mice studied was lower than
it is in classical human FSGS. This may be because mice are
resistant to developing proteinuria and/or because pathways
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that are activated in renal disease differ in mice and humans.
It is also possible that, since the recombinant reagent used
is made in a bacterial system and lacks glycosylation, it
may have lower potency than that which is expressed in
mammalian cells. Finally, it is possible that additional plasma
components are required to cause maximal proteinuria and
to result in renal disease that mimics human FSGS. Such
plasma components might include antibodies, lipoproteins,
or other cytokines or proteins that are also increased by
CLCF-1 or by substances generated by the kidney during
injury.
As anticipated from the known properties of CLCF-1, the
B-cell population producing IgG is expanded after infusion
of CLCF-1 into mice. B-cell responses to CLCF-1 may also
be important in progression of FSGS to fibrosis and renal
failure. A recent report documents elevated concentrations
of a number of autoantibodies in the plasma of patients
with recurrent FSGS [48]. Targets of these antibodies include
proteins expressed by podocytes. It may be that CLCF-1
contributes to B-cell activation that, in turn, leads to generation of these and other antibodies. Rituximab, an anti-Bcell antibody that is useful in autoimmune diseases including
membranous nephropathy, has reduced proteinuria in some
patients with FSGS including those with recurrence after
transplantation. Rituximab has been proposed to act directly
to protect podocytes [49] and this effect, as well as decreased
antibody synthesis, may be important in FSGS. Thus, CLCF1 may play a dual role in the pathogenesis of recurrent
FSGS, first, by signaling that directly alters podocyte function
and, second, by activating B cells and enhancing antibody
production.
Unfortunately, currently available assays are not sufficiently sensitive to permit measurement of CLCF-1 in patient
samples. Preliminary studies suggest that normal concentrations may be only a few pg/mL and that concentrations in
some FSGS patients may be over 100 pg/mL (unpublished
data). There is no information regarding potential urinary
excretion of CLCF-1 or potential elevation in other disease
states. Our findings regarding 𝑃alb activity suggest kinetics
similar to those of immunoglobulins and it is possible that
CLCF-1 is bound to plasma proteins or other molecules. 𝑃alb
activity is relatively constant over many months or years and
does not vary with filtration rate or degree of proteinuria.
If CLCF-1 is indeed directly related to this activity, then it
too may remain stable over long periods. We are actively
investigating these relationships and the potential clinical
utility of CLCF-1 measurements. If an active role for CLCF1 in glomerular injury is confirmed, therapy to block its
effects might induce remission or arrest of progression in
FSGS. Therapy might include use of humanized antibodies to
CLCF-1 itself, soluble receptors, or cytokine traps to prevent
receptor activation. Therapy that blocks the effects of CLCF1 may provide targeted protection without adverse effects
since no essential role of CLCF-1 has been identified after
fetal development. Alternatively, inhibition of JAK/STAT
activation using currently available small molecules may be
protective and have an acceptable side-effect profile.
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5. Summary and Conclusions
CLCF-1 is expressed in cells of bone marrow and peripheral
blood as well as other tissues. It activates STAT3 in peripheral
blood cells, renal cortex, and glomeruli, alters IgG expression
in B cells, increases glomerular 𝑃alb , and activates cultured
podocytes. It causes albuminuria in mice and results in
early focal glomerular scarring during chronic infusion. At
least some of these effects are dependent on activation of
the canonical JAK/STAT pathway. We interpret the increase
in 𝑃alb and activation of podocytes by CLCF-1 as well as
increased renal cortical and glomerular pSTAT as evidence
that CLCF-1 may play a role in FSGS. The finding that a
specific inhibitor of JAK2 activation protects 𝑃alb is consistent
with a central role for the JAK/STAT pathway in early
glomerular responses. We propose that alterations in immune
cell function and elevation of specific autoantibodies may also
contribute to the syndrome of FSGS and to its posttransplant
recurrence. The data in this report suggest an injurious rather
than a protective role for CLCF-1 and related cytokines and
open new areas of investigation related to cytokine function
and cellular injury and to the etiology and progression of
renal disease and to the potential for novel targeted therapy
for FSGS in selected patients.
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